ArticleTherapeutic advances in hematology2026
Prevalence and factors associated with anemia among people living with HIV taking dolutegravir-based antiretroviral therapy at debre markos compressive specialized hospital, debre markos, northwest Ethiopia, 2024: A cross-sectional study.
Article in Therapeutic advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anemia is a common hematological complication in people living with HIV (PLHIV), contributing to increased morbidity and mortality. PLHIV are vulnerable to anemia due to chronic inflammation, opportunistic infections, nutritional deficiencies, and the adverse effects of antiretroviral therapy (ART). Despite the favorable safety and efficacy profile of dolutegravir (DTG)-based regimens, emerging evidence has raised concerns about potential hematologic abnormalities, underscoring the need to investigate anemia among PLHIV on DTG-based therapy. Objective: To assess the prevalence of anemia and its associated factors among PLHIV receiving DTG-based ART at Debre Markos Comprehensive Specialized Hospital (DMCSH) in Northwest Ethiopia. Design: An institutional-based cross-sectional study. Methods: This study was conducted among 417 participants enrolled between March 1, 2024, and June 30, 2024, at the ART clinic of DMCSH. Participants were selected using a systematic sampling technique. Socio-demographic data were collected through a structured questionnaire, anthropometric measurements were taken, and clinical data were extracted from patient medical records using a standardized checklist. Hemoglobin levels were measured using the HemoCue® Hb 301 System. The collected data were coded and entered into Epidata version 4.6, then exported to SPSS version 26 for analysis. Logistic regression was conducted to identify factors associated with anemia, with a p-value of < 0.05 considered statistically significant. Result: The prevalence of anemia among PLHIV on DTG-based ART was 32.6% (95% CI: 28.1, 37.1). Among those diagnosed with anemia, 69.1% had mild anemia, 26.5% had moderate anemia, and 4.4% had severe anemia. Factors significantly associated with anemia included increasing age (AOR = 1.04; 95% CI: 1.02-1.07), female sex (AOR = 1.80; 95% CI: 1.12-2.89), duration of HIV infection ≥ 7 years (AOR = 1.88; 95% CI: 1.10-3.23), CD4 T-cell count < 500 cells/mm Conclusion: Anemia is a moderate public health issue among PLHIV on DTG-based ART. Factors such as female sex, increasing age, duration of HIV infection ≥ 7 years, CD4 T-cell counts < 500 cells/mm
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.